海外の治験の状況「1」での検索結果
1037件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not recruiting
- Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
- Herpes Simplex
- Australia, Belgium, Canada, Denmark, Estonia, France, Greece, Hungary, Iceland, Lithuania, Netherlands, New Zealand, Norway, Romania, Spain, Sweden, United Kingdom, United States
- 2005-09-21
Not recruiting
- Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
- Prophylaxis for Herpes Simplex
- Australia, Austria, Belgium, Canada, Denmark, France, Germany, Puerto Rico, South Africa, Spain, Switzerland, United States
- 2008-06-16
Not recruiting
- A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
- Pancreatic Cancer;Pancreatic Cancer;Pancreatic Cancer;Pancreatic Cancer
- Australia, New Zealand, Spain
- 2010-08-25
Not Recruiting
- WORTH (which one is right here?): Randomised, crossover study to identify predictive baseline characteristics of response to pioglitazone or vildagliptin as second or third line therapy in patients with Type 2 diabetes
- Type 2 diabetes; Type 2 diabetes;Metabolic and Endocrine - Diabetes
- New Zealand
- 2018-11-23
Not Recruiting
- A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
- Hepatocellular Carcinoma;C22.0 - Malignant neoplasm: Liver cell carcinoma
- Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Philippines, Portugal, Romania, Spain, Sweden, Switzerland, Taiwan, Province of China, Thailand, United States
- 2012-05-09
Not recruiting
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
- Non-Small Cell Lung Cancer;Non-Small Cell Lung Cancer;Non-Small Cell Lung Cancer;Non-Small Cell Lung Cancer
- Argentina, Austria, Brazil, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Puerto Rico, Romania, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2010-07-16
Not recruiting
- A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
- Hepatocellular Carcinoma;Hepatocellular Carcinoma;Hepatocellular Carcinoma;Hepatocellular Carcinoma
- Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Hungary, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Norway, Philippines, Portugal, Puerto Rico, Romania, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United States
- 2010-06-02
Not Recruiting
- OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC Open, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatment for patients with undetectable EGFR-status in metastatic colorectal cancer. - OPERA
- metastasized colorectal cancer MedDRA version: 8.1 Level: LLT Classification code 10052358 Term: Colorectal cancer metastatic
- Austria, Germany
- 2005-11-11
Not recruiting
- In search of the most effective protocol to treat hypoglycaemia in type 1 diabetes: a randomised trial testing 3 different hypoglycaemia treatment protocols for resolution of hypoglycaemia and symptoms in adolescents and adults with type 1 diabetes
- Diabetes
- ,Outside, New Zealand
- 2014-06-24
Not recruiting
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.
- This current study is being conducted in healthy volunteers to learn about the way this drug behaves in the body when it is given at different doses. The study will also be conducted in patients with Hepatitis C genotype 1.
- ,Outside, New Zealand
- 2014-03-21